BiotechTube

Letermovir 480 mg [PREVYMIS]

Phase 1Recruiting
2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

End-Stage Kidney Disease (ESKD)

Conditions

End-Stage Kidney Disease (ESKD)

Trial Timeline

Sep 1, 2025 → Dec 1, 2027

NCT ID
NCT07101055

About Letermovir 480 mg [PREVYMIS]

Letermovir 480 mg [PREVYMIS] is a phase 1 stage product being developed by Merck for End-Stage Kidney Disease (ESKD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07101055. Target conditions include End-Stage Kidney Disease (ESKD).

What happened to similar drugs?

8 of 9 similar drugs in End-Stage Kidney Disease (ESKD) were approved

Approved (8) Terminated (0) Active (1)
✅donepezil HCl + donepezil HClEisaiApproved
✅Zepatier + Ribavirin + SofosbuvirMerckApproved
✅Anti-Thymocyte Globulin vs Campath-1H vs DaclizumabRocheApproved
✅RanolazineGilead SciencesApproved
✅Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisoneSanofiApproved
✅rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimusSanofiApproved
✅Pioglitazone + placebo comparatorBaxterApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07101055Phase 1Recruiting
NCT06066957Phase 2Recruiting

Competing Products

20 competing products in End-Stage Kidney Disease (ESKD)

See all competitors
ProductCompanyStageHype Score
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPAAstellas PharmaPre-clinical
30
donepezil HCl + donepezil HClEisaiApproved
43
paricalcitolAbbViePhase 3
40
daptomycin + daptomycinMerckPhase 1
29
MK-2060 + PlaceboMerckPhase 2
35
Zepatier + Ribavirin + SofosbuvirMerckApproved
43
MK-2060 + PlaceboMerckPhase 1
29
daptomycinMerckPhase 1
29
MK-2060MerckPhase 1
29
MK-2060 + PlaceboMerckPhase 1
29
Anti-Thymocyte Globulin vs Campath-1H vs DaclizumabRocheApproved
43
AvacopanAmgenPhase 1
29
RanolazineGilead SciencesApproved
43
Bosutinib + Bosutinib + Bosutinib + BosutinibPfizerPhase 1
29
CP-690,550PfizerPhase 1
29
BelataceptBristol Myers SquibbPre-clinical
26
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisoneSanofiApproved
43
Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin inductionSanofiPhase 2
35
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimusSanofiApproved
43
ISIS 416858 + PlaceboBayerPhase 2
32